Natalia Sonicheva-Paterson

Natalia Sonicheva-Paterson

Auto-generated profile, based on publicly available information

Natalia Sonicheva-Paterson

Tenaya Therapeutics

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
MTMario Torrado
Mario Torrado
GFGermán Fernández
Germán Fernández
CGChristian A. Ganoza
Christian A. Ganoza
EMEmilia Maneiro
Emilia Maneiro
DGDiego García
Diego García
LMLorenzo Monserrat
Lorenzo Monserrat
Here we report an infant with clinical findings suggestive of Jervell and Lange-Nielsen syndrome (JLNS), including a prolonged QT interval (LQTS) and chronic bilateral sensorineural deafness. NGS analysis revealed one known heterozygous pathogenic missense variant, KCNQ1 p.R259L, previously associated with LQTS but insufficient to explain the cardioauditory disorder. In a screening of proximal intronic regions, we found a heterozygous variant, KCNQ1 c.1686−9 T > C, absent from controls and previously undescribed. Several splicing prediction tools returned low scores for this intronic variant. Driven by the proband’s phenotype rather than the neutral predictions, we have characterized this rare intronic variant. Family analysis has shown that the proband inherited the missense and the intronic variants from his mother and father, respectively. A minigene splicing assay revealed that the intronic variant induced an additional transcript, arising from skipping of exon 14, which was translated into a truncated protein in transfected cells. The splice-out of exon 14 creates a frameshift in exon 15 and a stop codon in exon 16, which is the last exon of KCNQ1. This mis-spliced transcript is expected to escape nonsense-mediated decay and predicted to encode a truncated loss-of-function protein, KCNQ1 p.L563Kfs*73. The analysis of endogenous KCNQ1 expression in the blood of the proband’s parents detected the aberrant transcript only in the patient’s father. Taken together, these analyses confirmed the proband’s diagnosis of JLNS1 and indicated that c.1686−9 T > C is a cryptic splice-altering variant, expanding the known genetic spectrum of biallelic KCNQ1 variant combinations leading to JLNS1.

14 August 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MKMaria Kharlap
Maria Kharlap
RMRoman Myasnikov
Roman Myasnikov
TPT. О. Pavlunina
T. О. Pavlunina
SBS. A. Beregovskaya
S. A. Beregovskaya
NSN. A. Sonicheva
N. A. Sonicheva
KDKarapet Davtyan
Karapet Davtyan
Clinical case demonstrates a cardiovascular phenotype of Fabry disease — rare inherited disorder, linked with female sex. Clinically manifest Fabry disease is described in female patient with paroxysmal atrial fibrillation. The specifics of differential diagnostics described, as of management, and indications for genetic diagnostics and prescription of genotype-specific enzyme replacement therapy.

28 August 2025 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
Evgeny ZhelyakovEvgeny Zhelyakov
Evgeny Zhelyakov
NSNatalia Sonicheva-Paterson
Natalia Sonicheva-Paterson
SASvetlana Alexandrova
Svetlana Alexandrova
VTViktor Tcivkovskii
Viktor Tcivkovskii
AAAndrey Andrei Ardashev
Andrey Andrei Ardashev
Background: Cardiac laminopathies, associated with mutations in the LMNA gene, are a rare inherited disorder characterized by a broad range of clinical manifestations. There are currently no data on the association between supraventricular re-entrant tachycardias and LMNA-related cardiomyopathy. Case summary: A 26-year-old male presented with either wide-QRS tachycardia with a left bundle branch block (LBBB) pattern or narrow QRS tachycardia, as well as a history of palpitations since age 15. Echocardiography showed no overt structural heart disease. Electrophysiological studies confirmed the diagnosis of orthodromic atrioventricular re-entrant tachycardia mediated by a concealed left posterolateral accessory pathway (AP), with transient LBBB and dual AV-node physiology, characterized by single echo beats. A short-run, asymptomatic episode of atrial fibrillation was induced. Cardiac magnetic resonance (CMR) imaging demonstrated myocardial hyperaemia, subepicardial late gadolinium enhancement, and a small pericardial effusion, initially interpreted as myocarditis according to the modified Lake Louise criteria. A family history of pacemaker implantation and cardiac death at age 65 of the patient’s grandfather, a history of re-entrant arrhythmia recurrence following ablation, and further CMR deteriorations led to genetic counselling. Genetic testing identified a heterozygous pathogenic variant in the LMNA gene (NM_170707.3.456_457insTCTC, NP_733821.1.Glu154GlnfsX2), classified as likely pathogenic and associated with laminopathy. Discussion: This case raises the question of whether the combination of re-entrant arrhythmias is coincidental or an early indicator of LMNA-related cardiomyopathy.

6 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LGLeila Gandaeva
Leila Gandaeva
Olga S. ChumakovaOlga S. Chumakova
Olga S. Chumakova
YDYulia I. Davidova
Yulia I. Davidova
RMRoman Myasnikov
Roman Myasnikov
NSNatalia A. Sonicheva-Paterson
Natalia A. Sonicheva-Paterson
KSKirill Savostyanov
Kirill Savostyanov
Background. The genetic etiology of hypertrophic cardiomyopathy (HCM) is complex and population-specific, yet Russian HCM patients remain understudied. Methods. Between 2015-2025, unrelated pediatric and adult HCM patients were genotyped in a single laboratory. Children were sequenced with a 404-gene panel and adults with a 17-gene panel. Genotype-phenotype correlations were assessed for carriers of the most frequent variant, MYBPC3 c.3697C>T , and compared with patients harboring other MYPBC3 variants. Haplotype analysis explored its potential founder effect. Results. The cohort comprised 315 children (mean age 11.7 years, 61% male; 127 infant-onset) and 3,409 adults (mean age 47.5 years, 58% male). Genotype-positive rates were 89% in children and 28% in adults. Sarcomeric and RASopathy variants accounted for 35% and 33% of infant-onset, 56% and 17% of childhood-onset, and 22% and 0.4% of adult-onset genotyped cases, respectively. The MYBPC3 c.3697C>T variant was identified in 83 patients (2.2%). Compared with controls (n = 85), carriers (n = 58) more often had left ventricular ejection fraction below 50% (9% vs. 1%, p = 0.038), left atrial dilation (76% vs. 47%, p = 0.001), and supraventricular arrythmias (45% vs. 25%, p = 0.027). Pediatric carriers showed no left ventricular outflow tract obstruction (0% vs. 29%, p = 0.024) and fewer conduction disturbances (13% vs. 48%, p = 0.029). Intervention rates and outcomes were similar across ages. Haplotype analysis was inconclusive for founder effect. Conclusions. The genetic spectrum of HCM in Russian population largely mirrors Western data. Within MYBPC3 -associated HCM, the c.3697C>T variant is linked to a milder, nonobstructive pediatric phenotype and increased hypokinetic progression in adults but does not influence overall outcomes. Its high prevalence likely reflects a combination of founder and recurrent mutational events.

12 November 2026 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
SHSoledad García Hernandez
Soledad García Hernandez
LRLuis De la Higuera Romero
Luis De la Higuera Romero
JLJose María Larrañaga-Moreira
Jose María Larrañaga-Moreira
NMNerea Mora-Ayestaran
Nerea Mora-Ayestaran
MVMaria Valverde-Gómez
Maria Valverde-Gómez
JOJuan Pablo Ochoa
Juan Pablo Ochoa
BACKGROUND: MYBPC3 truncating variants ( MYBPC3tv ) represent the most common genetic substrate in hypertrophic cardiomyopathy, yet carriers show substantial phenotypic variability despite a shared mechanism of haploinsufficiency. The contribution of additional genetic variants to this variability remains incompletely defined. METHODS: We analyzed 11 991 unrelated hypertrophic cardiomyopathy probands undergoing clinical genetic testing. Analyses focused on MYBPC3tv carriers stratified by additional intermediate-effect variants (IEVs) or second monogenic variants. IEVs were further classified as sarcomeric or nonsarcomeric. All probands were genetically characterized at a single center using standardized sequencing protocols, with uniform ascertainment of IEVs throughout the study period. Primary outcomes included age-related penetrance, maximal left ventricular wall thickness, and major adverse cardiovascular events; independent predictors were assessed by a multivariable Cox regression model. RESULTS: Among 2767 genotype-positive probands, MYBPC3 accounted for 47.6% of cases, with truncating variants representing 81.9% of MYBPC3 -positive individuals. Within MYBPC3tv carriers, additional variants were associated with a stepwise gradient of disease severity. Median age at diagnosis decreased from 48 years in isolated carriers to 42 years in MYBPC3tv +IEV and 28 years in double-monogenic carriers, whereas mean wall thickness increased from 21.3 to 24.1 and 26.3 mm, respectively. In multivariable analyses, cumulative genetic burden remained an independent predictor of major adverse cardiovascular event. Sarcomeric IEV carriers (hazard ratio, 10.3 [95% CI, 2.3–28.7]) and biallelic MYBPC3 carriers (hazard ratio, 23.2 [95% CI, 5.3–115.0]) exhibited the highest risk, although estimates in these subgroups should be interpreted cautiously given the limited number of events. All biallelic MYBPC3 carriers were diagnosed in childhood. CONCLUSIONS: Cumulative rare variant burden explains a subset of the phenotypic heterogeneity among MYBPC3tv carriers, defining a hierarchical gradient of disease expression. Intermediate-effect alleles and second monogenic variants, particularly biallelic MYBPC3 , identify higher-risk subgroups that may benefit from intensified surveillance, individualized management, and guided therapies.